NOS Catalytic Activity of Cell Homogenates or Intact B-CLL Cells
B-CLL No. . | Treatment . | NOS Activity (pmol/min/mg) A/Cell Homogenates . |
---|---|---|
1 | No | 27 ± 4 |
IgG1 | 22 ± 5 | |
Anti-CD23 | 52 ± 8 | |
2 | No | 18 ± 3 |
IgG1 | 22 ± 6 | |
Anti-CD23 | 56 ± 11 | |
NOS Activity (pmol/106 cells) B/Intact Cells | ||
3 | No | 1.0 ± 0.4 |
IgG1 | 1.9 ± 0.5 | |
Anti-CD23 | 6.7 ± 1.1 | |
4 | No | 1.2 ± 0.4 |
IgG1 | 0.2 ± 0.2 | |
Anti-CD23 | 5.6 ± 1.2 | |
5 | No | 2.4 ± 0.6 |
IgG1 | 1.0 ± 0.4 | |
Anti-CD23 | 9.0 ± 2.2 | |
6 | No | 0.6 ± 0.3 |
IgG1 | 0.6 ± 0.5 | |
Anti-CD23 | 7.5 ± 1.4 |
B-CLL No. . | Treatment . | NOS Activity (pmol/min/mg) A/Cell Homogenates . |
---|---|---|
1 | No | 27 ± 4 |
IgG1 | 22 ± 5 | |
Anti-CD23 | 52 ± 8 | |
2 | No | 18 ± 3 |
IgG1 | 22 ± 6 | |
Anti-CD23 | 56 ± 11 | |
NOS Activity (pmol/106 cells) B/Intact Cells | ||
3 | No | 1.0 ± 0.4 |
IgG1 | 1.9 ± 0.5 | |
Anti-CD23 | 6.7 ± 1.1 | |
4 | No | 1.2 ± 0.4 |
IgG1 | 0.2 ± 0.2 | |
Anti-CD23 | 5.6 ± 1.2 | |
5 | No | 2.4 ± 0.6 |
IgG1 | 1.0 ± 0.4 | |
Anti-CD23 | 9.0 ± 2.2 | |
6 | No | 0.6 ± 0.3 |
IgG1 | 0.6 ± 0.5 | |
Anti-CD23 | 7.5 ± 1.4 |
The NOS activity of six different B-CLL cell samples was determined by measuring, in duplicate, the conversion of14C-L-arginine into 14C-L-citrulline, either by cell lysates for two of them (A) or by intact cells for the other four cases (B). B-CLL cells were incubated overnight in medium alone or containing 10 μg/mL of anti-CD23 MoAb or control IgG1. Cell homogenates (A) were prepared at the end of the incubation time and their NOS enzymatic activity was tested over a 30-minute period. Alternatively, radiolabeled arginine was added at the beginning of the culture and the formation of radiolabeled citrulline in cell-free supernatants (B) was estimated at the end of the culture. Results (mean ± SD of duplicate samples) are expressed either in pmol/min/mg or pmol/106 cells.